Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DIOSynVax next-generation influenza vaccine
- Development stage
- Preclinical
- Lead developer
- DIOSynVax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DIOSynVax's next-generation influenza vaccine is a broadly protective candidate designed to provide cross-strain immunity against multiple influenza strains. Developed using the proprietary Digital Immune Optimized Synthetic Vaccine (DIOSynVax) platform and Vaccine Antigen Payload (VAP) technology, the vaccine utilizes computational biology and protein structure analysis to design synthetic antigens. These antigens target highly conserved regions of key influenza viral proteins, specifically hemagglutinin (HA), neuraminidase (NA), and the M2 ion channel. This approach aims to overcome the limitations of traditional seasonal vaccines by providing broader and longer-lasting protection against viral variability. As of mid-2025, the program is in the IND-enabling stage and ready for human clinical trials.
- Other names
- supra-seasonal influenza vaccineDIOS-flu
02
Targets
CHRM2 (M2)HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on DIOSynVax next-generation influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DIOSynVax next-generation influenza vaccine.